Equities research analysts expect Alkermes Plc (NASDAQ:ALKS) to announce earnings of ($0.17) per share for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Alkermes’ earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.06). Alkermes posted earnings of $0.07 per share during the same quarter last year, which would indicate a negative year over year growth rate of 342.9%. The company is scheduled to issue its next quarterly earnings report on Tuesday, October 22nd.
On average, analysts expect that Alkermes will report full-year earnings of $0.35 per share for the current fiscal year, with EPS estimates ranging from $0.26 to $0.53. For the next year, analysts forecast that the business will report earnings of ($0.08) per share, with EPS estimates ranging from ($1.20) to $0.21. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Alkermes.
Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Thursday, July 25th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.20. The firm had revenue of $279.90 million for the quarter, compared to analysts’ expectations of $251.40 million. Alkermes had a negative return on equity of 4.13% and a negative net margin of 17.10%. The firm’s revenue for the quarter was down 8.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.29 EPS.
Shares of ALKS stock opened at $22.21 on Friday. The stock has a market capitalization of $3.47 billion, a PE ratio of -317.21 and a beta of 1.80. Alkermes has a 52-week low of $19.85 and a 52-week high of $46.98. The stock’s 50-day moving average price is $22.32 and its 200 day moving average price is $27.79. The company has a quick ratio of 2.69, a current ratio of 2.98 and a debt-to-equity ratio of 0.25.
Large investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its stake in Alkermes by 58.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 361,457 shares of the company’s stock valued at $10,664,000 after purchasing an additional 133,233 shares during the period. Geode Capital Management LLC raised its stake in Alkermes by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 1,546,255 shares of the company’s stock valued at $45,602,000 after purchasing an additional 76,621 shares during the period. Los Angeles Capital Management & Equity Research Inc. raised its stake in Alkermes by 214.4% during the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 273,982 shares of the company’s stock valued at $9,998,000 after purchasing an additional 186,840 shares during the period. BNP Paribas Arbitrage SA raised its stake in Alkermes by 46.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 76,089 shares of the company’s stock valued at $2,776,000 after purchasing an additional 24,304 shares during the period. Finally, SG Americas Securities LLC raised its stake in Alkermes by 755.8% during the 1st quarter. SG Americas Securities LLC now owns 101,982 shares of the company’s stock valued at $3,721,000 after purchasing an additional 90,066 shares during the period. 96.66% of the stock is currently owned by institutional investors and hedge funds.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.